Keros Therapeutics (KROS) Misses Q4 EPS by 134c

Keros Therapeutics (NASDAQ: KROS) reported Q4 EPS of ($1.34), $1.34 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $140 thousand versus the consensus estimate of $0 .

For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c